Skip to main content

Advertisement

Table 1 Patient characteristics at baseline

From: Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme

Characteristic  
Patients, N 74
Gender, n (%)  
 Male 46 (62.2)
 Female 28 (37.8)
Age, years, median (range) 56 (23–79)
Time from diagnosis, months, median (range) 31 (5–206)
Melanoma diagnosis, n (%)  
 Cutaneous 57 (77.0)
 Uveal 9 (12.2)
 Mucosal 2 (2.7)
 Unknown 6 (8.1)
Presence of brain metastases 11 (14.9)
M stage, n (%)  
 M0 (unresectable stage III) 2 (2.7)
 M1a 16 (21.6)
 M1b 2 (2.7)
 M1c 53 (71.6)
 Unknown 1 (1.4)
ECOG PS  
 0 43 (58.1)
 1 29 (39.2)
 2 2 (2.7)
LDH  
 Median (range), units/L 466 (139–4416)
 >Upper limit of normal (480 units/L), n (%) 37 (50)
Number of prior therapies for metastatic disease, median (range) 2 (1–5)
  1. ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, PS performance status.